Condition: Leukemia, Juvenile Myelomonocytic · JMML · JCML · Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
This description comes directly from the study's public registry record.
Ellynore Florendo · 323-361-3022 · eflorendo@chla.usc.edu
Suganya Rajendran · 323-361-8835 · srajendran@chla.usc.edu
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Recruiting |
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Children's Hospital of Colorado | Denver, Colorado, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Children's Hospital of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Indiana University/Riley Hospital for Children | Indianapolis, Indiana, United States | Recruiting |
| Sidney Kimmel Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| C.S. Mott Children's Hospital | Ann Arbor, Michigan, United States | Recruiting |
| Children's Mercy Hospital | Kansas City, Missouri, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05849662